Move Aside, Moderna: This mRNA Stock Is Sitting on a Cash Pile and a Deep Cancer Pipeline
Moderna isn't the only mRNA biotech stock that could deliver big gains for investors. BioNTech (NASDAQ: BNTX) has billions in cash on its books and a cancer treatment pipeline that could transform it from a COVID-19 vaccine maker into a major force in oncology. With several promising therapies advancing through clinical trials, this biotech could already have the ingredients to fuel its next chapter of growth. Image source: Getty Images. Continue reading